Efficacy of rabeprazole in patients with reflux esophagitis: A single-center, open-label, practice-based, postmarketing surveillance investigation

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 12, 2002, Pages 810-820

  Kinoshita, Yoshikazu ^p   Hirayama, Michiaki ^q   Hamada, Shiro ^q   Yoshida, Tsukasa ^a   Ishii, Nobumitsu ^b   Nakata, Ryo ^c   Chishima, Jyoichi ^d   Handa, Yuichi ^e   Saito, Keiji ^f   Takayama, Tetsuo ^g   Tatsumi, Sei ^q   Iishi, Hiroyasu ^h   Kohli, Yoshihiro ⁱ   Fujita, Shinya ^j   Tanaka, Hiroshi ^k   Ookuchi, Souhei ^q   Suzuki, Seiyuu ^q   Koyama, Takanori ^l   Yoshida, Takasuke ^m   Kabemura, Teppei ⁿ   Matsumoto, Katsuhiko ^o   more..

^a AKITA CITY HOSPITAL   (Japan)

^b Kohsei Chuo General Hospital   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d Fukaya Red Cross Hospital   (Japan)

^e SAITAMA RED CROSS HOSPITAL   (Japan)

^f KAMEDA MEDICAL CENTER   (Japan)

^g Sakashita Hospital   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ Aiseikai Yamashina Hospital   (Japan)

^j KYOTO KATSURA HOSPITAL   (Japan)

^k Division of Clinical Pathology   (Japan)

^l Saga Prefectural Hospital   (Japan)

^m University of Occupational and Environmental Health School of Medicine   (Japan)

ⁿ SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^o Keiwakai Ohita Oka Hospital   (Japan)

^p SHIMANE UNIVERSITY   (Japan)

^q NONE

more..

Author keywords

Modified Los Angeles classification; Pariet ; Rabeprazole; Reflux esophagitis

Indexed keywords

ANTACID AGENT; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 4 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SCORING SYSTEM;

EID: 0036935403     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80085-6     Document Type: Article

References (21)

1. Maekawa T, Kinoshita Y, Okada A, et al. Relationship between severity and symptoms of reflux oesophagitis in elderly patients in Japan. J Gastroenterol Hepatol. 1998;13:927-930.
2. Kinoshita Y, Kawanami C, Kishi K, et al. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut. 1997;41:452-458.
3. Labentz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442-1447.
4. Yanai A, Yabana T, Tokuchi S, et al. Evaluation of E3810, a novel proton-pump inhibitor on reflux esophagitis. Modern Physician. 1994;14(Suppl):124-136.
5. 2 receptor antagonists (2): Clinical effects on reflux esophagitis; similarities and differences. Clin Gastroenterol. 1993;8:37-44.
6. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to grade IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology. 1997;112:1798-1810.
7. +-ATPase. Folia Pharmacol Jpn. 1993;102:389-397.
8. +. ATPase is correlated with the rate of acid activation of the inhibitor. Biochem Pharmacol. 1990;39:661-667.
9. Inoue M, Matsumoto Y, Murakami Y, et al. Effect of a proton pump inhibitor, E3810 on intragastric pH; 24 hr intragastric pH monitoring. Jpn Arch Int Med. 1994;41:99-106.
10. Iwasaki A, Karihara R, Arakawa Y, et al. Effects of a proton pump inhibitor, rabeprazole, and gastric acid secretion. Jpn Pharmacol Ther. 1999;27:205-212.
11. Hongo M, Kimpara T, Moriyama S, et al. Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers. Tohoku J Exp Med. 1998;186:43-50.
12. Robinson M, Maton PN, Rodriguez S, et al. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1997;11:973-980.
13. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12:1079-1089.
14. 2 receptor antagonists and proton pump inhibitors). J N Remedies Clin. 1999;48:34-42.
15. Yoshida Y, Manakata A, Takashugi T, et al. Clinical assessment of E3810 on reflux esophagitis. Modern Physician. 1994;14(Suppl):137-147.
16. Good Post-Marketing Surveillance Practice. Japanese Ministry of Health and Welfare Ordinance No. 10, March 10, 1997.
17. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology. 1996;111:85-92.
18. Hoshihara Y. Reflux esophagitis at the time of PPI - Los Angeles Classification of Esophagitis. Modern Physician. 1995;15(Suppl):8-11.
19. Makuuchi H, Machimura T, Mizutani K, et al. A healing process of reflux esophagitis - Staging by the use of a pigment endoscopy. Stomach Intest. 1992;27:1029-1038.
20. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med. 1982;307:1547-1552.
21. Johnson LF, DeMeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol. 1974;62:325-332.